Skip to main content
    B

    Bright Minds Biosciences Inc (DRUG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $54.21
    +3.50 (+6.90%)

    Market Cap: $532.76M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    100%(8/8)
    Avg Surprise
    +47.14%
    Streak
    8 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.41
    Range$-0.39 - $1.23
    7 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.82
    Range$-2.72 - $-1.21
    5 analysts
    EPS Revisions
    4
    0
    7d
    4
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-2.78+34.6%
    60d ago$-2.78+34.6%
    30d ago$-1.84+1.0%
    7d ago$-1.84+1.0%
    Current$-1.82
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.82---
    Sep 26EST
    		-$0.41---
    Jun 26
    Reported Aug 14
    		$-0.17N/A+87.77%Beat+77.0%
    Mar 26
    Reported May 20
    		$-1.09$-1.26+13.49%Beat-275.9%
    Dec 25
    Reported Feb 12
    		$-0.97$-1.18+17.80%Beat-9800.0%
    Sep 25
    Reported Dec 23
    		$-0.57$-1.00+42.86%Beat-235.3%
    Jun 25
    Reported Aug 14
    		$-0.74$-0.88+15.91%Beat-2149.9%
    Mar 25
    Reported May 15
    		$-0.29$-0.39+25.64%Beat-204.0%
    Dec 24
    Reported Feb 13
    		$0.01N/A+102.00%Beat+103.1%
    Sep 24
    Reported Nov 27
    		$-0.17N/A+71.67%Beat+43.7%
    Jun 24
    Reported Aug 14
    		$0.04N/AN/ABeat+112.5%
    Mar 24
    Reported May 15
    		$-0.10N/AN/ABeat-19.1%
    Dec 23
    Reported Feb 12
    		$-0.32N/AN/ABeat-235.6%
    Sep 23
    Reported Dec 29
    		$-0.30N/AN/ABeat-98.7%
    Jun 23
    Reported Aug 14
    		$-0.29$0.00N/AMiss-69.0%
    Mar 23
    Reported May 15
    		$-0.08$0.00N/AMiss+72.9%
    Dec 22
    Reported Feb 7
    		$-0.10$0.00N/AMiss+70.5%
    Sep 22
    Reported Dec 28
    		$-0.15$0.00N/AMiss+36.7%
    Jun 22
    Reported Aug 12
    		$-0.17N/AN/ABeat+29.9%
    Mar 22
    Reported May 15
    		$-0.30N/AN/ABeat-132.4%
    Dec 21
    Reported Feb 14
    		$-0.33N/AN/ABeat-
    Sep 21
    Reported Dec 29
    		$-0.24N/AN/ABeat-
    Jun 21
    Reported Jul 17
    		$-0.24N/AN/ABeat-
    Mar 21
    Reported Jun 17
    		$-0.13N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-26.84EV/EBITDAN/A
    Price/FCF-39.03xFCF Yield-2.56%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-13.60%ROIC-11.21%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio121.97xQuick Ratio121.97x
    Trading Statistics
    Beta0.23Avg Volume145.74K
    52-Week High$123.7552-Week Low$47.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$51.71
    SMA 20$53.09
    SMA 50$65.06
    SMA 200$75.08
    EMA 10$52.46
    EMA 20$54.42
    EMA 50$61.15
    EMA 200$67.97

    MACD

    Line: -3.32Signal: -4.26Hist: 0.94

    ADX

    ADX: 36.5+DI: 19.6-DI: 26.2

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down76.0
    PSAR$48.61

    Bollinger Bands

    Upper Band$60.75
    Lower Band$45.43
    %B Position2885%(Upper)
    Band Width0.57

    RSI (14-Day)

    Neutral
    45.2

    Momentum Oscillators

    Stoch %K53.2
    Stoch %D46.9
    Williams %R-18.4
    ROC (10d)10.2%
    Momentum5.00
    CCI (20d)8.7
    MFI (14d)62.2

    Volatility Measures

    ATR (14d)$3.45(6.4%)
    StdDev (20d)3.83
    Hist Vol60.9%(High)

    Volume Flow

    VWAP$53.71
    OBV-3.4M
    AD Line-4.2M
    CMF (20d)-0.096

    Volume Metrics

    Avg Vol (20d)152.1K
    Vol Ratio0.8x
    VWMA (20d)$52.63

    Pivot Points

    R3$56.66
    R2$54.81
    R1$52.76
    Pivot Point$50.91
    S1$48.86
    S2$47.01
    S3$44.96

    Advanced Oscillators

    TSI-30.04
    Ultimate Osc53.6
    KST-219.58

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$19,973$20,130$19,772$12,212$11,638N/AN/AN/A$18,113$18,112$18,113$18,112
    Gross Profit$-19,973$-20,130$-19,772$-12,212$-11,638N/AN/AN/A$-18,113$-18,112$-18,113$-18,112
    Operating Expenses$11.71M$15.55M$6.90M$5.66M$3.30M$3.35M$1.62M$791,310$-234,742$558,062$1.70M$1.55M
    R&D$9.50M$13.27M$5.66M$4.78M$2.69M$2.56M$1.05M$416,055$566,749$105,180$1.23M$1.09M
    SG&A$2.15M$2.13M$990,110$603,962$479,260$589,820$462,728$346,012$320,644$363,595$364,581$422,564
    Operating Income$-11,733,107$-15,569,156$-6,904,082$-5,664,542$-3,296,310$-3,352,081$-1,624,651$-791,310$234,742$-558,062$-1,698,998$-1,550,479
    Interest Income$2.79M$2.69M$818,265$529,538$476,231$509,381$4,318$6,007$14,987$0$0$0
    Interest Expense$4,174$5,592$6,572$0$1.95M$0$0$0$1,241$2,126$2,971$3,786
    Income Before Tax$-2,461,807$-10,633,956$-7,565,318$-4,085,603$-5,242,970$-2,950,385$49,610$-773,441$229,903$-574,141$-1,684,267$-1,527,998
    Income Tax Expense$0$0$0$185,149$0$0$0$0$-4$-2$-14,731$-57,934
    Net Income$-2,461,807$-10,633,956$-7,565,318$-4,085,603$-5,242,970$-2,950,385$49,610$-773,441$229,903$-574,141$-1,684,267$-1,527,998
    EBITDA$-11,713,133$-10,608,234$-7,545,529$-4,068,594$-5,227,125$-3,329,600$71,143$-754,422$248,016$-556,029$-1,666,154$22,481
    EBIT$-11,733,106$-10,628,364$-7,565,318$-4,085,603$-5,242,970$-3,352,081$49,610$-773,441$229,903$-574,141$-1,684,267$-1,527,998
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DRUG

    News

    Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 6.6% - Here's Why

    Bright Minds Biosciences (NASDAQ:DRUG) saw its stock price rise by 6.6% to $54.04, despite a 96% drop in trading volume. The company, focused on neuropsychiatric and neurological disorder therapeutics...

    MarketBeat•10/15/26•Somewhat-Bullish

    Bright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Wolfe Research

    Wolfe Research initiated coverage on Bright Minds Biosciences (NASDAQ:DRUG) with an "outperform" rating and a $150 price target...

    MarketBeat•10/15/26•Bullish

    Bright Minds Biosciences Inc. (NASDAQ:DRUG) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

    Bright Minds Biosciences Inc. (NASDAQ:DRUG) has received a "Moderate Buy" consensus rating from ten research firms, with an average 12-month price target of $143.83. The company...

    MarketBeat•10/14/26•Bullish

    Bright Minds Biosciences Inc. (DRUG) Stock Price, News, Quote & History

    This Yahoo Finance page provides a comprehensive overview of Bright Minds Biosciences Inc. (DRUG) stock, including its current price, market performance...

    Yahoo! Finance Canada•10/8/26•Somewhat-Bullish

    Bright Minds Biosciences (NASDAQ:DRUG) Hits New 1-Year Low - Here's What Happened

    Bright Minds Biosciences (NASDAQ:DRUG) shares reached a new 52-week low of $47.23 on Thursday, despite reporting better-than-expected quarterly EPS of -$0.17 against estimates of -$1.22. Analysts maintain a "Moderate...

    MarketBeat•10/8/26•Neutral

    DRUG Valuation and Fair Value

    P/E
    -26.8x
    P/FCF
    -39.0x
    P/B
    2.5x
    See GNG's fair value

    DRUG Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -11.2%
    ROE
    -13.6%
    FCF yield
    -2.6%

    DRUG Competitors

    CompanyTicker
    ZimVie IncZIMV
    Shattuck Labs IncSTTK
    Valneva SE ADRVALN
    Puma Biotechnology IncPBYI
    Silence Therapeutics PLCSLN
    Evolent Health IncEVH
    Sagimet Biosciences Inc. Series A Common StockSGMT
    Oncology Institute IncTOI

    Sector: Healthcare

    DRUG Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    1
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    0

    DRUG Bull Case vs Bear Case

    Bull case

    • DRUG beat EPS estimates in 100.0% of its last 8 reported quarters.
    • 100.0% of DRUG's analyst ratings are Buy or Strong Buy.

    DRUG Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    47.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.41

    Frequently Asked Questions About DRUG

    Does DRUG pay dividends?

    Bright Minds Biosciences Inc (DRUG) does not currently pay a regular dividend.

    What is DRUG's market cap?

    Bright Minds Biosciences Inc (DRUG) has a market capitalization of $532.76M with a current stock price of $54.21.

    Related stocks

    Sector: Healthcare

    All stocks starting with D

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In